Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401081 | 0.82 | LOXL2 (0.69) | LOXL2HRH3AHRHRH4AOC3 | |
| SCHEMBL28338445 | 0.82 | LOXL2 (0.69) | LOXL2HRH3AHRHRH4AOC3 | |
| SCHEMBL29403791 | 0.82 | LOXL2 (0.69) | LOXL2HRH3AHRHRH4AOC3 | |
| SCHEMBL31059889 | 0.82 | LOXL2 (0.69) | LOXL2HRH3AHRHRH4AOC3 | |
| SCHEMBL7169246 | 0.82 | LOXL2 (0.69) | LOXL2HRH3AHRHRH4AOC3 | |
| SCHEMBL28335219 | 0.80 | LOXL2 (0.67) | LOXL2HRH3AHRAOC3MTNR1A | |
| SCHEMBL108061 | 0.78 | LOXL2 (0.64) | LOXL2HRH3AHRHRH4AOC3 | |
| SCHEMBL219867 | 0.78 | LOXL2 (0.64) | LOXL2HRH3AHRHRH4AOC3 | |
| SCHEMBL3022232 | 0.78 | LOXL2 (0.64) | LOXL2HRH3AHRHRH4AOC3 | |
| SCHEMBL19919274 | 0.78 | LOXL2 (0.64) | LOXL2HRH3AHRHRH4AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040783-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2721011-B1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | UNIV EMORY (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170081314-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-9518044-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20140179750-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2721011-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | Emory University (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012177618-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2012-12-27 | — | — | WO | disclosed |
| CN-101195672-B | Method for producing olefin-copolymerization catalyst and method for producing olefin-copolymers | SUMITOMO CHEMICAL CO | 2011-07-06 | — | — | CN | disclosed |
| US-7732540-B2 | Process for producing olefin copolymerization catalyst and process for producing olefin copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20090018012-A1 | Process for Producing Olefin Copolymerization Catalyst and Process for Producing Olefin Copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| CN-101195672-A | Method for producing olefin-copolymerization catalyst and method for producing olefin-copolymers | SUMITOMO CHEMICAL CO (JP) | 2008-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040783-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGES | LOXL2 135/4885HRH3 1305/4885AHR 740/4885 |
| US-20170081314-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGES | LOXL2 135/4885HRH3 1305/4885AHR 740/4885 |
| US-20140179750-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | PTGER2, PTGES2, PTGES | LOXL2 135/4885HRH3 1305/4885AHR 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.